PTP||Why having CV death risk reduction benefit is important in T2D management?

backArrow Back
organProtectonlogo

HEART

Why having CV death risk reduction benefit is important in T2D management?

video previous buttonPrevious video play buttonPlay video next buttonNext

EXPERTS GROUP

Prof. Sarah Jarvis

Member of British Empire, General Practitioner Visiting Professor of General Practice, University of Huddersfield

HEART
HF is often undiagnosed, what does HF indication mean for the use of SGLT2i in T2D?
784 days
HEART
What does data for SGLT2i in HF regardless of EF mean for Endocrinologists / primary care practitioners?
744 days
HEART
How to communicative CV death and hospitalization of heart failure risk redution benefits effectively to T2D patients?
744 days
PC-SSK-101710